Fabry Disease clinical trials at UCSD
2 in progress, 1 open to eligible people
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
open to eligible people ages 18 years and up
This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease.
La Jolla, California and other locations
Extension Study of 1 mg/kg Pegunigalsidase Alfa in Patients With Fabry Disease
Sorry, accepting new patients by invitation only
The objective of PB-102-F60 is to evaluate the long-term safety, tolerability, and efficacy parameters of 1 mg/kg pegunigalsidase alfa administered intravenously every other week in adult Fabry patients who have successfully completed studies PB-102-F03, PB-102-F20 or PB-102-F30.
La Jolla, California and other locations
Our lead scientists for Fabry Disease research studies include Eric Adler, MD.
Last updated: